About NBE Therapeutics
NBE Therapeutics is a Healthcare company based in Basel (Switzerland) founded in 2012, and was acquired by Boehringer Ingelheim in December 2020. Antibody-drug conjugates for cancer treatment are developed. It operates on a HealthTech model. NBE Therapeutics has raised $65.86 million across 11 funding rounds from investors including Boehringer Ingelheim, Boehringer Ingelheim Venture Fund and PPF Group. NBE Therapeutics offers products and services including Antibody-Drug Conjugates (ADCs). Its focus areas include Biotechnology and Oncology. Its legal entity is NBE-Therapeutics AG.
Company details
NBE Therapeutics is engaged in the development of next-generation antibody-drug conjugates (ADCs) for oncology treatments. The company targets solid tumors through innovative in-house technologies, aiming to increase survival rates and improve the quality of life for cancer patients worldwide. A pipeline of ADC product candidates in various stages of development is maintained to advance clinical phases and provide selective drugs. The focus is placed on precision medicine to transform cancer care with long-lasting immune oncology effects.
- Headquarters Basel, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website nbe-therapeutics.com
- Social LinkedIn
- Acquired by Boehringer Ingelheim (Dec 2020)
- Legal Name Nbe-Therapeutics Ag
- Total Equity Funding$65.86M (USD)
in 11 rounds
- Latest Funding Round$22M (USD), Series C
Jan 2020
- InvestorsBoehringer Ingelheim
& 4 more
- Acquired byBoehringer Ingelheim
(Dec 2020)
Products & Services of NBE Therapeutics
NBE Therapeutics offers a comprehensive portfolio of products and services, including Antibody-Drug Conjugates (ADCs).
Innovative ADCs are developed for targeted cancer treatment.
Funding Insights of NBE Therapeutics
NBE Therapeutics has successfully raised a total of $65.86M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $22 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.86M
- Total Rounds 11
- Last Round Series C — $22M
- Investors Count 4
Latest 10 of 11 funding rounds of NBE Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $22M | Series C | – | Boehringer Ingelheim Venture Fund, PPF Group | – |
| Jun 2018 | $20.13M | Series B | – | PPF Group | |
| Jan 2018 | $240,216 | Grant | – | – | – |
| Nov 2016 | $20.55M | Series B | – | PPF Group | |
| Jan 2016 | $1.1M | Grant | – | – | – |
| Feb 2015 | $3.18M | Series A | – | Boehringer Ingelheim Venture Fund | – |
| Nov 2014 | $623,376 | Grant | – | – | |
| Mar 2014 | $1.14M | Grant | – | – | – |
| Oct 2013 | $1.9M | Grant | – | – | – |
| Jun 2013 | $1.05M | Grant | – | – | – |
5 investors in total: 5 institutional.
Investors in NBE Therapeutics
NBE Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Boehringer Ingelheim, Boehringer Ingelheim Venture Fund and PPF Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
PPF Group is engaged in international investment across diverse sectors. | 1991 | ppf.eu | Prague, Czech Republic | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
| systemsx.ch | ||||
Generic drugs and clinical research services are provided globally. | 1885 | boehringer-ingelheim.com |
Investor details for NBE Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NBE Therapeutics
31 people are tracked at NBE Therapeutics (6 in leadership, 4 in board & advisors, 21 in team).
| Name | Role | Group |
|---|---|---|
Giuliano Bellapadrona | Director ADC CMC | Leadership |
Ulrike Fiedler | Senior Director Program Management and Pipeline Innovation | Leadership |
Gerd Munzert | Chief Clinical Officer | Leadership |
Carl Deutsch, PhD, MBA | Chief Scientific Officer | Leadership |
Marco Meier | Head of in vivo unit | Leadership |
Mariarosa Spina Horn | Human Resources Business Partner | Leadership |
Thomas Winkler | Scientific Advisor | Board & advisors |
Anthony W. Tolcher | Scientific Advisor | Board & advisors |
Jaap Verweij | Scientific Advisor | Board & advisors |
Alfred Zippelius | Scientific Advisor | Board & advisors |
Melanie R. | Research Associate | Team |
Lukas Bammert | Research Scientist | Team |
Rémy Gébleux | Senior Scientist | Team |
Alexandra Musch | Research associate | Team |
Manuel Biehler | Research Assistant | Team |
Timo Lüthi | Research Assistant I | Team |
Antoine Kraemer | Research Associate | Team |
Julie Fierle | Scientist | Team |
Malaury Schappler | Research Associate In Immuno-oncology | Team |
Andrea Brychcy | Research Assistant | Team |
11 more people are available in the full profile.
Complete people profiles for NBE Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NBE Therapeutics
4 dated milestones of NBE Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded NBE Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $22.0M.
- Exit Acquired by Boehringer Ingelheim.
Web traffic of NBE Therapeutics
The website of NBE Therapeutics (nbe-therapeutics.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▲ 87.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nbe Therapeutics
Complete news archive for NBE Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NBE Therapeutics
NBE Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
NBE Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
NBE Therapeutics is a funded company, having raised a total of $65.86M across 11 funding rounds to date. The company's 1st funding round was a Grant of $1.05M, raised on Jan 2013.
NBE Therapeutics is engaged in the development of next-generation antibody-drug conjugates (ADCs) for oncology treatments. The company targets solid tumors through innovative in-house technologies, aiming to increase survival rates and improve the quality of life for cancer patients worldwide. A pipeline of ADC product candidates in various stages of development is maintained to advance clinical phases and provide selective drugs. The focus is placed on precision medicine to transform cancer care with long-lasting immune oncology effects.
NBE Therapeutics offers Antibody-Drug Conjugates (ADCs).
NBE Therapeutics has 5 investors. Key investors include Boehringer Ingelheim, Boehringer Ingelheim Venture Fund, PPF Group, Novo Holdings, and The Swiss Initiative in Systems Biology.
NBE Therapeutics operates through Nbe-Therapeutics Ag.
Yes. NBE Therapeutics was acquired by Boehringer Ingelheim in December 2020.